RAC 2.37% $1.65 race oncology ltd

The RAC 3-Pillar Trifecta, page-157

  1. 277 Posts.
    lightbulb Created with Sketch. 139
    Why did it fail as an anticancer agent when it is such a potent FTO stopper, yet bisantrene hammers all sorts of cancers?

    It was interesting enough to CoH that they will continue to research it's FTO stopping ability. along with bisantrene.

    F trying to write a comment on this website on the Web browser on your phone.

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.